• Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

(970) 818-8343

info@cetya-therapeutics.com
Cetya Therapeutics Cetya Therapeutics
  • Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

A pioneering leader in histone deacetylase inhibitor research, focusing on largazole analogs

Learn more

About Cetya Therapeutics

Cetya Therapeutics, Inc. is a Delaware C-Corporation formed in 2012 to develop histone deacetylase inhibitors (HDACi) based on analogs of largazole. Some of these analogs incorporate receptor ligands, which enable them to target specific cell types or tumors. This targeting approach is unique for HDACi and, together with increased potency and selectivity, differentiates Cetya’s compounds. More than 30 largazole analogs have been synthesized, some with best-in-class HDACi profiles, including:

  • Biochemical and cell-based potency
  • Up-regulation of fetal hemoglobin expression
  • In vivo anti-cancer activity

 

Cetya is seeking corporate partners to assist in advancing its largazole analog portfolio into clinical studies in a number of different therapeutic indications.

our company

News

Cetya Therapeutics Announces Phase II STTR Grant Award

 $1,000,000 NIH Grant will further development of Cetya’s HDAC inhibitor CT-101 for treatment of sickle…

September 23, 2019Read More

Cetya Therapeutics announces advanced industries award

$170,000 Colorado Grant will advance Cetya’s novel targeted HDAC inhibitor program.

December 1, 2017Read More

Cetya Therapeutics announces STTR grant

$240,000 Grant will allow evaluation of Cetya’s HDAC inhibitors for treatment of sickle cell disease.

September 22, 2017Read More

Collaborations

img-logo-2x
cancercenter

HDACi with best-in-class potency and isoform-selective drug candidates

Learn More

Contact Us

We're currently offline. Send us an email and we'll get back to you, asap.

Send Message

Menu

  • Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

Contact

  • (303) 895-8216
  • info@cetya-therapeutics.com

© 2018 · Cetya Therapeutics